Accelerate your hit-to-lead optimization. We provide robust electrophysiology platforms to identify liabilities early, mitigating off-target toxicity risks in cardiac and CNS drug discovery.
Our customized ion channel screening service is designed for global pharmaceutical and biotechnology companies. By utilizing state-of-the-art automated systems alongside the gold-standard manual patch clamp assay, we deliver precise mechanistic insights and highly reproducible safety data. With a validated library of over 100+ channels, our CRO operations ensure that off-target liabilities are rapidly identified to support smooth IND transitions.
| Parameter | Specification |
|---|---|
| Target Library | 100+ Validated Cell Lines |
| Assay Formats | Manual Patch Clamp & APC |
| Throughput Capacity | Medium to Ultra-High |
| Business Models | FTE / FFS / Hybrid |
"The manual patch clamp data provided by ICE Bioscience was incredibly clean and consistent. Their hERG panel evaluation directly supported our successful IND filing this year."
Director of Safety Pharmacology
Top 50 Global Biopharma
"We partnered via an FTE model for a complex target not in their standard library. Their cell line engineering team delivered a validated stable cell line weeks ahead of schedule."
VP of Early Discovery
Boston-based Biotech
"Their automated patch clamp capabilities allowed us to screen hundreds of compounds rapidly, seamlessly integrating into our hit-to-lead optimization process."
Lead Medicinal Chemist
Innovative Therapeutics Inc.
Safety Pharmacology
A deep dive into mitigating hERG liability and ensuring robust cardiovascular safety profiles using advanced patch clamp techniques.
Read ArticleStandard turnaround time (TAT) is typically 2-4 weeks depending on the compound volume and selected assay formats, ensuring rapid data delivery for early-stage drug discovery.
Yes, we provide highly flexible FTE (Full-Time Equivalent) and FFS (Fee-For-Service) business models tailored to your specific assay requirements and budget.
Absolutely. Our electrophysiology data and final reports are generated under stringent quality control parameters designed to fully support global IND filings.
We leverage automated patch clamp for high-throughput primary screening and hit identification. Manual patch clamp is utilized as the gold-standard for precise, definitive mechanism-of-action and high-sensitivity safety profiling.
Our robust cell line engineering team can rapidly develop, validate, and optimize custom stable cell lines expressing your proprietary targets for downstream screening.
Our comprehensive panels evaluate investigational compounds against a wide array of cardiac (e.g., hERG, Nav1.5) and neural channels to identify potential liabilities, allowing medicinal chemists to design away from toxicity early.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
